- Teva Pharmaceuticals has announced FDA approval for Austedo XR as a once-daily treatment option for TD and HD chorea in adults.
- Austedo XR is now available in four new tablet strengths and is designed to help those with chronic, involuntary movements manage their conditions effectively.
- The approval of Austedo XR offers a convenient treatment option with proven efficacy and tolerability data to help patients control their symptoms.
- Patients with TD may see symptom improvement within two weeks, while those with HD chorea may experience a significant reduction in TMC score over three years.
- Teva is committed to assisting eligible patients with access to Austedo XR through financial assistance programs to help manage out-of-pocket costs.
Source link
Pharmacists, Neurology, Psychiatry & Mental Health, Internal Medicine